Valuation: BioLife Solutions

Market Cap 1.89B 1.68B 1.54B 1.4B 2.64B 178B 2.71B 18.49B 7.39B 94.5B 7.09B 6.94B 298B P/E 2024
-58.9x
P/E 2025 -251x
Enterprise Value 1.79B 1.59B 1.46B 1.33B 2.5B 169B 2.57B 17.49B 6.99B 89.38B 6.7B 6.56B 282B EV / Sales 2024
13.7x
EV / Sales 2025 11x
Free-Float
97.09%
Yield 2024 *
-
Yield 2025 -
1 day+3.51%
3 months+14.23%
6 months+79.16%
Current year+59.68%
Current year 17.86
Extreme 17.86
39.76
1 year 17.86
Extreme 17.86
39.76
3 years 9.92
Extreme 9.92
39.76
5 years 8.92
Extreme 8.9201
54.81
10 years 1.44
Extreme 1.44
60.67
Manager TitleAgeSince
Corporate Officer/Principal - 2020-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
10/6/26 Issuer sale

Director

-57,995 0.1211%
10/6/26 Issuer sale

Director

-53,156 0.1110%
10/6/26 Free

Founder

560,638 1.1703%
Change 5-day change 1-year change 3-year change Capi.($)
+3.51%-.--%+40.04%+238.09% 1.89B
-1.65%+8.64%-8.78%+18.53% 197B
-1.35%+7.48%-6.32%+21.31% 128B
-0.11%+7.96%+15.97%+44.49% 128B
-1.35%+2.74%-39.45%+9.67% 99B
-4.05%+2.77%-4.05%+74.04% 64.82B
+2.08%+7.67%+21.07%-17.52% 58.17B
-3.99%+16.45%-6.87%+56.23% 52.84B
-6.98%-14.56%-12.60%+42.69% 50.69B
-2.33%+3.96%+3.50%-7.86% 37.23B
Average -1.62%+6.20%+0.25%+47.97% 81.73B
Weighted average by Cap. -1.75%+7.54%-5.17%+27.04%

Financials

2024 2025
Net sales 82.25M 73.3M 67.04M 61.06M 115M 7.77B 118M 805M 322M 4.12B 309M 302M 12.99B 96.21M 85.74M 78.42M 71.42M 135M 9.09B 138M 942M 377M 4.82B 361M 353M 15.19B
Net income -20.18M -17.99M -16.45M -14.98M -28.24M -1.91B -29M -198M -79.03M -1.01B -75.76M -74.13M -3.19B -4.6M -4.09M -3.75M -3.41M -6.43M -434M -6.6M -44.99M -17.99M -230M -17.25M -16.88M -726M
Net Debt -79.04M -70.43M -64.42M -58.67M -111M -7.47B -114M -774M -309M -3.96B -297M -290M -12.48B -102M -91.14M -83.36M -75.92M -143M -9.67B -147M -1B -400M -5.12B -384M -376M -16.15B
Projected Income Statement - Annual - BioLife Solutions
Logo BioLife Solutions
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
Employees
155
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - BioLife Solutions
  1. Stock Market
  2. Stocks
  3. BLFS Stock